338 related articles for article (PubMed ID: 34503643)
1. An unusual case of acute myopericarditis after the first dose of capecitabine: Need for new cardioprotective strategies and risk stratification.
Meter M; Gavran I; Bajo D; Duplancic D
Int J Clin Pharmacol Ther; 2021 Dec; 59(12):775-779. PubMed ID: 34503643
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine-induced myopericarditis - A case report and review of literature.
Saunders S; Anwar M
J Oncol Pharm Pract; 2019 Jun; 25(4):1006-1010. PubMed ID: 29783917
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study.
Peng J; Dong C; Wang C; Li W; Yu H; Zhang M; Zhao Q; Zhu B; Zhang J; Li W; Wang F; Wu Q; Zhou W; Yuan Y; Qiu M; Chen G
Cancer Commun (Lond); 2018 May; 38(1):22. PubMed ID: 29764506
[TBL] [Abstract][Full Text] [Related]
4. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study.
Osterlund P; Kinos S; Pfeiffer P; Salminen T; Kwakman JJM; Frödin JE; Shah CH; Sorbye H; Ristamäki R; Halonen P; Soveri LM; Heervä E; Ålgars A; Bärlund M; Hagman H; McDermott R; O'Reilly M; Röckert R; Liposits G; Kallio R; Flygare P; Teske AJ; van Werkhoven E; Punt CJA; Glimelius B
ESMO Open; 2022 Jun; 7(3):100427. PubMed ID: 35798468
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy.
Karakulak UN; Aladağ E; Maharjan N; Övünç K
Turk Kardiyol Dern Ars; 2016 Jan; 44(1):71-4. PubMed ID: 26875134
[TBL] [Abstract][Full Text] [Related]
6. Fluoropyrimidine-Associated Cardiotoxicity: A Retrospective Case-Control Study.
Raber I; Warack S; Kanduri J; Pribish A; Godishala A; Abovich A; Orbite A; Dommaraju S; Frazer M; Peters ML; Asnani A
Oncologist; 2020 Mar; 25(3):e606-e609. PubMed ID: 32162823
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer.
Dyhl-Polk A; Vaage-Nilsen M; Schou M; Vistisen KK; Lund CM; Kümler T; Appel JM; Nielsen DL
Acta Oncol; 2020 Apr; 59(4):475-483. PubMed ID: 31931649
[No Abstract] [Full Text] [Related]
8. Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal.
Upshaw JN; O'Neill A; Carver JR; Dimond EP; Denlinger CS; Kircher SM; Wagner LI; Ky B; Brell JM
Clin Colorectal Cancer; 2019 Mar; 18(1):44-51. PubMed ID: 30348619
[TBL] [Abstract][Full Text] [Related]
9. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history.
Kelly C; Bhuva N; Harrison M; Buckley A; Saunders M
Eur J Cancer; 2013 Jul; 49(10):2303-10. PubMed ID: 23583220
[TBL] [Abstract][Full Text] [Related]
10. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity.
Deboever G; Hiltrop N; Cool M; Lambrecht G
Clin Colorectal Cancer; 2013 Mar; 12(1):8-14. PubMed ID: 23102544
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil.
Frickhofen N; Beck FJ; Jung B; Fuhr HG; Andrasch H; Sigmund M
Ann Oncol; 2002 May; 13(5):797-801. PubMed ID: 12075751
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine in breast cancer: the issue of cardiotoxicity during fluoropyrimidine treatment.
Molteni LP; Rampinelli I; Cergnul M; Scaglietti U; Paino AM; Noonan DM; Bucci EO; Gottardi O; Albini A
Breast J; 2010; 16 Suppl 1():S45-8. PubMed ID: 21050310
[TBL] [Abstract][Full Text] [Related]
13. Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.
Layoun ME; Wickramasinghe CD; Peralta MV; Yang EH
Curr Oncol Rep; 2016 Jun; 18(6):35. PubMed ID: 27113369
[TBL] [Abstract][Full Text] [Related]
14. Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review.
Saneeymehri SS; Markey KR; Mahipal A
J Oncol Pharm Pract; 2016 Jun; 22(3):552-5. PubMed ID: 25852107
[TBL] [Abstract][Full Text] [Related]
15. Fluoropyrimidine-Associated Cardiotoxicity.
Kanduri J; More LA; Godishala A; Asnani A
Cardiol Clin; 2019 Nov; 37(4):399-405. PubMed ID: 31587781
[TBL] [Abstract][Full Text] [Related]
16. Fluoropyrimidine-induced cardiotoxicity.
Depetris I; Marino D; Bonzano A; Cagnazzo C; Filippi R; Aglietta M; Leone F
Crit Rev Oncol Hematol; 2018 Apr; 124():1-10. PubMed ID: 29548480
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine-Induced Coronary Vasospasm.
Henry D; Rudzik F; Butts A; Mathew A
Case Rep Oncol; 2016; 9(3):629-632. PubMed ID: 27920693
[TBL] [Abstract][Full Text] [Related]
18. Report of two cases of acute cardiac adverse events in patients with colorectal carcinoma receiving oral capecitabine.
Lampropoulos S; Roditis P; Koulouris E; Zafiris A; Tzimou M; Kyratlidis K; Pavlidis K; Godwin SA; Kosmas C
Anticancer Drugs; 2017 Aug; 28(7):801-807. PubMed ID: 28489615
[TBL] [Abstract][Full Text] [Related]
19. Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series.
Saif MW; Garcon MC; Rodriguez G; Rodriguez T
In Vivo; 2013; 27(4):531-4. PubMed ID: 23812226
[TBL] [Abstract][Full Text] [Related]
20. Cardiotoxicity and capecitabine: a case report.
Singer M
Clin J Oncol Nurs; 2003; 7(1):72-5. PubMed ID: 12629938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
